Cargando…
Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479765/ https://www.ncbi.nlm.nih.gov/pubmed/30970533 http://dx.doi.org/10.3390/molecules24071382 |
_version_ | 1783413420657213440 |
---|---|
author | Teran-Saavedra, Nayelli Guadalupe Sarabia-Sainz, Jose Andre-i Silva-Campa, Erika Burgara-Estrella, Alexel J. Guzmán-Partida, Ana María Ramos-Clamont Montfort, Gabriela Pedroza-Montero, Martín Vazquez-Moreno, Luz |
author_facet | Teran-Saavedra, Nayelli Guadalupe Sarabia-Sainz, Jose Andre-i Silva-Campa, Erika Burgara-Estrella, Alexel J. Guzmán-Partida, Ana María Ramos-Clamont Montfort, Gabriela Pedroza-Montero, Martín Vazquez-Moreno, Luz |
author_sort | Teran-Saavedra, Nayelli Guadalupe |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for HCC. ASGPRs facilitate the recognition and endocytosis of molecules, and possibly vehicles with galactose end groups, by the liver. In this study, bovine serum albumin (BSA) was conjugated with lactose using a thermal treatment. The formation of lactosylated BSA (BSA-Lac) was confirmed by a change of the chemical structure, increased molecular mass, and Ricinus communis lectin recognition. Subsequently, the low-crosslinking BSA-Lac nanoparticles (LC BSA-Lac NPs) and high-crosslinking BSA-Lac nanoparticles (HC BSA-Lac NPs) were synthesized. These nanoparticles presented spherical shapes with a size distribution of 560 ± 18.0 nm and 539 ± 9.0 nm, as well as an estimated surface charge of −26 ± 0.15 mV and −24 ± 0.45 mV, respectively. Both BSA-Lac NPs were selectively recognized by ASGPRs as shown by biorecognition, competition, and inhibition assays using an in vitro model of HCC. This justifies pursuing the strategy of using BSA-Lac NPs as potential drug nanovehicles with selective direction toward hepatocellular carcinoma. |
format | Online Article Text |
id | pubmed-6479765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64797652019-04-30 Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma Teran-Saavedra, Nayelli Guadalupe Sarabia-Sainz, Jose Andre-i Silva-Campa, Erika Burgara-Estrella, Alexel J. Guzmán-Partida, Ana María Ramos-Clamont Montfort, Gabriela Pedroza-Montero, Martín Vazquez-Moreno, Luz Molecules Article Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for HCC. ASGPRs facilitate the recognition and endocytosis of molecules, and possibly vehicles with galactose end groups, by the liver. In this study, bovine serum albumin (BSA) was conjugated with lactose using a thermal treatment. The formation of lactosylated BSA (BSA-Lac) was confirmed by a change of the chemical structure, increased molecular mass, and Ricinus communis lectin recognition. Subsequently, the low-crosslinking BSA-Lac nanoparticles (LC BSA-Lac NPs) and high-crosslinking BSA-Lac nanoparticles (HC BSA-Lac NPs) were synthesized. These nanoparticles presented spherical shapes with a size distribution of 560 ± 18.0 nm and 539 ± 9.0 nm, as well as an estimated surface charge of −26 ± 0.15 mV and −24 ± 0.45 mV, respectively. Both BSA-Lac NPs were selectively recognized by ASGPRs as shown by biorecognition, competition, and inhibition assays using an in vitro model of HCC. This justifies pursuing the strategy of using BSA-Lac NPs as potential drug nanovehicles with selective direction toward hepatocellular carcinoma. MDPI 2019-04-09 /pmc/articles/PMC6479765/ /pubmed/30970533 http://dx.doi.org/10.3390/molecules24071382 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Teran-Saavedra, Nayelli Guadalupe Sarabia-Sainz, Jose Andre-i Silva-Campa, Erika Burgara-Estrella, Alexel J. Guzmán-Partida, Ana María Ramos-Clamont Montfort, Gabriela Pedroza-Montero, Martín Vazquez-Moreno, Luz Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma |
title | Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma |
title_full | Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma |
title_fullStr | Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma |
title_full_unstemmed | Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma |
title_short | Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma |
title_sort | lactosylated albumin nanoparticles: potential drug nanovehicles with selective targeting toward an in vitro model of hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479765/ https://www.ncbi.nlm.nih.gov/pubmed/30970533 http://dx.doi.org/10.3390/molecules24071382 |
work_keys_str_mv | AT teransaavedranayelliguadalupe lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma AT sarabiasainzjoseandrei lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma AT silvacampaerika lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma AT burgaraestrellaalexelj lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma AT guzmanpartidaanamaria lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma AT ramosclamontmontfortgabriela lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma AT pedrozamonteromartin lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma AT vazquezmorenoluz lactosylatedalbuminnanoparticlespotentialdrugnanovehicleswithselectivetargetingtowardaninvitromodelofhepatocellularcarcinoma |